Alnylam Pharmaceuticals (ALNY) Stock
Commercial RNA developer with approved rare disease medicines. Here's the price, business snapshot, and what's worth knowing about Alnylam Pharmaceuticals in July 2026.
Alnylam Pharmaceuticals (ALNY) is a biotechnology company that develops RNA interference (RNAi) therapeutics to silence disease-causing genes. Investors should know it has moved from research-stage to a commercial entity, with multiple approved medicines for rare genetic disorders — including treatments for hereditary ATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria — and a broad pipeline built on its GalNAc delivery platform. The business is growth-oriented: revenues depend on uptake of marketed drugs, pricing and successful launches of late-stage candidates. Key risks include trial outcomes, regulatory decisions, pricing pressures, manufacturing scale-up and competition from other modalities. With a market capitalisation near $62.13 billion, Alnylam may appeal to investors seeking exposure to innovative therapeutics, but it suits those comfortable with biotech volatility. This is general information for educational purposes only and not personalised investment advice; values can fall as well as rise.
Why It’s Moving
Alnylam Pharmaceuticals Soars as Analysts Praise 2026 Guidance and Biotech Momentum
- Needham elevated its price target on ALNY to $529 while maintaining a Buy rating, citing robust 2026 guidance that signals accelerated drug adoption and revenue growth.
- Multiple Wall Street analysts, including Freedom Capital Markets, upgraded the stock to Buy or Strong Buy, highlighting the company's constructive outlook and expanding market share in rare disease therapeutics.
- The broader biotech sector is experiencing a rotation into high-growth RNA-therapy companies, with investors interpreting Alnylam's recent clinical data as a catalyst for long-term value expansion.
Alnylam Pharmaceuticals Soars as Analysts Praise 2026 Guidance and Biotech Momentum
- Needham elevated its price target on ALNY to $529 while maintaining a Buy rating, citing robust 2026 guidance that signals accelerated drug adoption and revenue growth.
- Multiple Wall Street analysts, including Freedom Capital Markets, upgraded the stock to Buy or Strong Buy, highlighting the company's constructive outlook and expanding market share in rare disease therapeutics.
- The broader biotech sector is experiencing a rotation into high-growth RNA-therapy companies, with investors interpreting Alnylam's recent clinical data as a catalyst for long-term value expansion.
When is the next earnings date for ALNYLAM PHARMACEUTICALS INC (ALNY)?
The next earnings date for ALNY is expected to be on Thursday, July 30, 2026, based on the company's historical reporting schedule. This upcoming report will cover the financial results for the second quarter (Q2) of 2026. Investors should anticipate the announcement before the market opens, consistent with the company's typical pre-market release pattern. Please note that while this date is the current consensus estimate, the company has not yet formally confirmed the official publication date.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Alnylam Pharmaceuticals' stock with a target price of $495.04, indicating growth potential.
Financial Health
Alnylam Pharmaceuticals is generating strong profits and revenue, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ALNY
LNP Patent Holders Shape Drug Delivery Value 2025
The massive settlement between Moderna and Arbutus/Genevant highlights the critical value of the lipid nanoparticle (LNP) technology used in mRNA vaccines. This creates a potential investment opportunity in companies that hold key patents for drug delivery systems, as they may be poised for lucrative licensing deals or acquisitions.
Published: 4 March 2026
Explore BasketAI Drug Discovery | Biotech Investment Opportunities
NVIDIA and Eli Lilly have launched a $1 billion AI lab to revolutionize the drug discovery process. This partnership highlights a burgeoning investment opportunity in companies at the intersection of artificial intelligence and biotechnology.
Published: 13 January 2026
Explore BasketRNA Stocks (M&A Targets) Could See Premium Valuations
Novartis's $12 billion acquisition of Avidity Biosciences underscores the high value of RNA-based treatments for rare diseases. This deal could spark a wave of similar acquisitions, creating opportunities for other biotech companies with innovative RNA platforms.
Published: 27 October 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: 21 July 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: 15 July 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: 11 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
RNAi platform potential
Alnylam’s GalNAc delivery platform enables targeted gene silencing across liver-related diseases, which could drive long-term growth, though clinical and commercial execution matters.
Clinical catalysts ahead
Late-stage trial readouts and new approvals can be material share-price catalysts; remember that trial or regulatory setbacks can also move the stock substantially.
Rare-disease reach
Market opportunity centres on rare, high‑need conditions where few therapies exist, but pricing, access and competition will influence commercial outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
